Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Payables (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Payables for 4 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Payables fell 52.57% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 52.57% year-over-year, with the annual reading at $5.0 million for FY2025, 52.57% down from the prior year.
  • Payables for Q4 2025 was $5.0 million at Phathom Pharmaceuticals, up from $1.1 million in the prior quarter.
  • The five-year high for Payables was $12.6 million in Q4 2023, with the low at $1.1 million in Q3 2025.
  • Average Payables over 4 years is $6.8 million, with a median of $6.5 million recorded in 2023.
  • The sharpest move saw Payables skyrocketed 83.42% in 2024, then crashed 84.93% in 2025.
  • Over 4 years, Payables stood at $10.0 million in 2022, then increased by 26.05% to $12.6 million in 2023, then dropped by 16.62% to $10.5 million in 2024, then crashed by 52.57% to $5.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $5.0 million, $1.1 million, and $4.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.